Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Innovative therapies redefine treatment goals in multiple sclerosis (CROSBI ID 253357)

Prilog u časopisu | stručni rad

Lazibat, I ; Šamija RK ; Rotim, K. Innovative therapies redefine treatment goals in multiple sclerosis // Acta clinica Croatica, 55 (2016), 1; 125-133

Podaci o odgovornosti

Lazibat, I ; Šamija RK ; Rotim, K.

engleski

Innovative therapies redefine treatment goals in multiple sclerosis

The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding number of available therapies for relapsing forms of MS. Greater understand- ing of the degenerative aspects of MS pathogenesis is redefining treatment goals and creating new treatment strategies. The existing immunomodulation drugs (disease-modifying therapies, DMTs) used in MS treatment have shown only partial benefits in controlling disease progression, primarily by reducing the inflammation component. However, new therapies for MS have been shown to be effective in delaying disease progression by protecting against brain atrophy, which is considered the most important preindicator of future patient disability. The favorable effect on reducing brain atrophy suggests the potential neuroprotective or even neuroregenerative effects of new treatments, marking progress in the treatment of MS.

Multiple sclerosis – therapy ; Multiple sclerosis, relapsing-remitting – drug therapy ; Immunosuppressive agents – therapeutic use ; Treatment outcome

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

55 (1)

2016.

125-133

objavljeno

0353-9466

1333-9451

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost